BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Travere Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Travere Therapeutics\, Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05003986-10808@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Filspari (sparsentan): Phase 2 readout est. (NCT05003986)
DESCRIPTION:Filspari (sparsentan)\, phase 2\, Focal Segmental Glomeruloscle
 rosis.\nStudy: Study of Sparsentan Treatment in Pediatrics With Proteinuri
 c Glomerular Diseases\nEstimated primary completion: 12 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sparsentan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05003986
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
